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Background: Propofol is a widely used injectable anesthetic agent for induction and short-term maintenance in
dogs. A multi-dose formulation of propofol (MDP) has been developed which includes 2% benzyl alcohol as a
preservative. In order to document the use of the product under clinical conditions, MDP was tested in a prospective
clinical trial conducted at six sites within the United States. One hundred thirty-eight healthy, client-owned dogs were
assigned to one of six treatment groups based on premedicants (none, acepromazine/buprenorphine, midazolam/
buprenorphine, medetomidine/buprenorphine) and maintenance agents (MDP, inhaled anesthetic). Anesthesia was
induced by the intravenous administration of MDP given to effect. Physiological indices including heart rate, respiratory
rate and blood pressure were monitored prior to and during anesthesia induction, maintenance and recovery. Adverse
events, defined for severity by pre-established limits of these physiological values, as well as side effects, defined as any
observation outside the normal range, were noted.
Results: The mean intubation dose was 7.6 ± 2.1 mg/kg for MDP alone and 4.7 ± 1.3, 4.0 ± 1.0 mg/kg and
3.2 ± 1.4 mg/kg when buprenorphine was used in combination with midazolam, acepromazine and medetomidine,
respectively. Of the 32 adverse events, apnea (12 incidents), bradycardia (9 incidents) and hypotension (7 incidents)
were most frequently recorded. Emesis, cyanosis and second degree heart block were each noted once and
successfully resolved. The cause of a single death 2 days post-anesthesia was assessed as a surgical complication.
Conclusions: MDP was found to be acceptable for use in healthy dogs for induction and short term maintenance
of anesthesia when used alone and in combination with premedicants and inhaled anesthetics.
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A formulation of propofol intended for one-time use in
dogs has been approved in the United States since 1996
[1]. Since its introduction, propofol has gained wide-
spread acceptance as an anesthesia induction and short-
term maintenance agent in dogs. The drug has a rapid
onset of action and when used for short-term mainten-
ance, recovery times and quality are considered favorable
relative to inhaled anesthetic agents [2].
These single-use injectable preparations of propofol
available for veterinary use are oil-in-water emulsions
containing no preservative [1,3]. Hence the label recom-
mendation is that any drug that has not been used within* Correspondence: kmama@colostate.edu
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reproduction in any medium, provided the orsix hours after the bottle or vial has been penetrated
should be discarded to minimize the risk of contamination
and possible adverse consequences to the patient. This
can result in both drug waste and financial loss in many
veterinary practice situations. A formulation allowing
penetrated bottles to be stored and re-used for a period
of time without significant risk of contamination would
minimize these concerns.
One such alternative formulation of propofol has become
available for intravenous use in dogs. The preservative
in this formulation is 2% benzyl alcohol, a compound
that has been used as a preservative in other injectable
solutions (e.g., atropine) available for intravenous use. It has
been shown to be highly effective against gram positive
bacteria, molds and fungi, and moderately effective against
gram negative organisms [4]. The addition of benzyl alco-
hol as a preservative to the original propofol formulationLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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use shelf life [5]. Toxicity studies conducted under labora-
tory conditions on this formulation showed no significant
adverse events when administered to dogs at up to 3 times
the labeled induction dose [5].
The present study was designed to document the use




One hundred and thirty eight client-owned dogs were
enrolled in this study which was conducted at six sites,
including three university veterinary hospitals and three
privately owned veterinary clinics. Prior to inclusion a
physical examination was performed on all dogs and results
of a complete blood count and serum chemistry were
evaluated. Animals that had laboratory values outside
the normal range for a given facility, were pregnant, had
received an investigational drug or had been enrolled in
an investigational drug study within 30 days, or were cate-
gorized as ASA Category IV or V were excluded. Owner
consent for participation was obtained prior to enrolling
each animal in the study. Institutional animal care and
use or hospital management committee approval was
also obtained at Colorado State University, the University
of Tennessee, the University of Florida and the private vet-
erinary practices participating in the study. Once enrolled,
demographic data including age, breed, gender and body
weight were recorded.
Study design
This study was designed to include at least 100 cases in
which MDP was utilized as the induction agent prior to
maintenance with MDP or an inhalant anesthetic. This
number is considered adequate by regulatory agencies to
determine safety for veterinary products under conditions
of use. Dogs were assigned to one of six treatment groups
based on premedicant combinations and maintenance
agents they were to receive (Table 1). Group assignments
were not randomized but rather were left to the discretion
of the investigator who evaluated the patient’s physical
status and laboratory findings and considered the nature
and duration of the procedure to be performed. The
use of anticholinergics during any phase of anesthetic
management was also permitted at the discretion of the
on-site investigator and injectable carprofen was allowed
post-operatively.
Due to the necessity of determining an appropriate
anesthesia protocol for each dog, the study was not
blinded. In addition to choice of the treatment group to
which a patient was assigned, the on-site investigator
was free to choose the dose and route of drugs used for
premedication in each dog within broadly establishedguidelines designed to be in keeping with the wide range
of dosages used in clinical practice. This information
was recorded for all animals.
In animals receiving premedicants, anesthesia induction
with MDP was initiated after the full effect of premedicants
was present; MDP was delivered over a period of 60 –
90 seconds via an intravenous (IV) catheter until endo-
tracheal intubation could be achieved. The start time and
dose of propofol required for anesthesia induction and dur-
ation over which the dose was administered were recorded.
To permit evaluation of the safety and efficacy of MDP in
the face of repeated withdrawals, each vial was numerically
identified and the duration of individual vial usage and the
number of withdrawals per vial were noted.
Anesthesia was maintained with successive intravenous
injections of MDP (groups 1–3) or with either isoflurane
or sevoflurane (groups 4–6) in oxygen administered
using a semi-closed rebreathing or non-rebreathing
(Bain) circuit and out of circle vaporizer based on ani-
mal size and individual practice standards. Animals
were allowed to breathe spontaneously. Maintenance
agents (MDP or inhaled anesthetic) were administered
to maintain an adequate plane of anesthesia for the
procedure being performed; the dose and time of add-
itional MDP administration was noted and the vaporizer
setting (for the inhaled agent) was recorded at fixed in-
tervals. The use of propofol to supplement inhalation
anesthesia in the event of a sudden lightening of the
anesthetic plane was permitted and recorded. In an effort
to allow for the variability in clinical practice, oxygen
supplementation was optional for dogs in the propofol
maintenance groups.
Behavioral and physiologic variables
The quality of induction and time to intubation from
start of MDP administration were recorded. Times to
extubation, sternal recumbency and standing following
the last dose of MDP or from discontinuation of inhal-
ation agent administration were also noted for all ani-
mals. Investigators assigned subjective scores reflecting
the quality of induction, maintenance and recovery
(Excellent, Good, Fair, Poor) based on previously pub-
lished scales [6]. For example, an excellent induction
would include a smooth rapid transition to recumbency
without vocalization and muscle movement, whereas a
poor induction would include muscle fasciculation,
urination or defecation and inappropriate vocalization. The
duration and type of intervention or surgical procedure
were also noted.
Total anesthesia duration was considered from the
time of intubation to the conclusion of drug administra-
tion (last dose of MDP for groups 1 – 3 and vaporizer
off for inhaled anesthesia groups 4–6). The duration of
drug induced recumbency following the induction dose
Table 1 Group classifications and duration of procedures




Duration of procedure (min)
Mean ± SD and range2
1 None Multidose propofol 23 14.6 ± 15.8
0.3-62
2 Midazolam/buprenorphine Multidose propofol 25 19.7 ± 14.6
2-64
3 Acepromazine/buprenorphine Multidose propofol 25 18.0 ± 14.3
5-56
4 Midazolam/buprenorphine Inhalant 22 41.1 ± 18.4
10-75
5 Acepromazine/buprenorphine Inhalant 22 73.6 ± 53.1
20-203
6 Medetomidine/buprenorphine Inhalant 21 38.3 ± 20.4
7-98
1Anticholinergics were considered optional for all treatment groups. Anesthesia in all dogs was induced with multi-dose propofol. See text for additional detail.
2Statistically significant (p < 0.05) differences between treatment group means for duration of procedure: 4 > 1 and 5 > 1, 2, 3, 4, 6.
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propofol (groups 1–3) using the time from intubation
to the time that the first additional (maintenance) dose
was administered.
Rectal temperature (T), heart rate (HR), respiratory
rate (RR), mucus membrane color, indirect systolic (S),
diastolic (D) and mean (M) arterial blood pressure (BP)
were recorded prior to premedication and again prior to
anesthesia induction. Heart rate was either obtained by
palpation of the pulse or recorded from an oscillometric
non-invasive BP monitor used to obtain S, D and M arterial
pressures prior to and during anesthesia; cuff size approxi-
mated 40% of the circumference of the limb and was placed
proximal to the carpus or hock. Electrocardiographic
(ECG) monitoring was not required for the study, but
was performed in some animals at the discretion of
the investigator. Hemoglobin saturation with oxygen
(as measured by a pulse oximeter, SpO2) and end-tidal
carbon dioxide (as measured by a capnograph, ETCO2)
were monitored continuously and recorded immediately
following intubation and again at 5, 10, 20, 30 minutes
after intubation and then at 30 minute intervals during
anesthesia maintenance. Respiratory rate was measured
by observation of the chest wall or recorded from the
capnograph. A thermistor or thermometer was placed
in the esophagus or rectum, respectively, to record body
temperature at the aforementioned time points during
anesthesia maintenance.
Observations which included predetermined parameters
of central nervous system activity (e.g., excitation, ex-
cessive depression/death), and limits for cardiovascular
(e.g., hypotension, arrhythmias) and respiratory (e.g.,
tachypnea, apnea, hemoglobin oxygen saturation) system
parameters, were recorded if observed prior to and atany time during anesthesia and recovery until the patient
reached sternal recumbency. Observations of physiological
values outside the normal range were considered side
effects. Adverse events were defined as extremes in values
or prolonged duration for these observations: apnea for
greater than 120 seconds, a heart rate less than 50 beats
per minute, mean arterial pressure less than 50 mm Hg,
any abnormal ECG rhythm which upon evaluation was
considered by the site investigator to be harmful to the
patient, hemoglobin saturation with oxygen of less than
80% (for any duration) or between 80 and 90% for more
than 3 minutes. Additional side effects such as excessive
salivation and emesis were also noted.
Statistical analysis
Differences among the six treatment groups in patient
characteristics were statistically evaluated via either
chi-square analysis (gender and ASA status) or one-factor
analysis of variance followed by Tukey’s procedure for
pair-wise mean comparisons (age and weight).
Data on each quantitative response variable (e.g., time
to sternal recumbency and HR at times both prior to
and following induction) were statistically summarized
(mean and standard deviation) and were analyzed via
analysis of variance (ANOVA) with treatment group as a
fixed effect and also study site as a random effect. Because
both the variation among sites and the interaction between
sites and treatment groups were found to be uniformly
non-significant (p > 0.10), the final ANOVA model included
only treatment group as a fixed effect. The timed recovery
variables (e.g., time to sternal recumbency) required a loga-
rithmic transformation to satisfy the ANOVA assumption
of Normality, which was evaluated via the Shapiro-Wilk
test. Pair-wise comparisons of treatment group means were
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values for multiple testing. A p value of ≤ 0.05 was con-
sidered significant.
Results
Because both the variation among sites and the interaction
between sites and treatment groups in the ANOVA of each
quantitative variable that included study site as a random
effect were found to be uniformly non-significant (p > 0.10)
the results presented here are those from the ANOVA
which included only treatment group.
Patient demographics (age, weight, gender) and ASA
status are presented in Table 2. Briefly, patients ranged
in age from 0.25 to 17 years and represented multiple
breeds. Both genders were well represented. The majority
of patients were classified as ASA I and the remainder as
ASA II. Among the breeds included in the study, there
were 34 mixed breed, 13 Labrador Retrievers, 7 Yorkshire
Terriers, 5 each of King Charles Spaniel, Golden Retriever,
Jack Russell Terrier and Miniature or Toy Poodle, and 34
other breeds which were represented by 4 or less individ-
uals. No significant differences in patient numbers, ASA
status or weight were identified across groups. The mean
age of group 2, in which mass removals were common,
was greater than those of groups 4 and 5, in which spays
and neuters were common. Also, differences in gender
upon enrollment were observed between groups; there
were statistically significant differences in number of
intact versus spayed/neutered animals, but not malesTable 2 Patient demographics by treatment group
Group 1 2 3
N 23 25 25
Age (Ye
Mean 4.65 7.70 4.84
SD 3.97 3.42 4.16
Range (0.8-14.0) (0.8-13.5) (0.3-12.0)
Weight
Mean 15.5 21.6 15.7
SD 10.6 14.5 13.4
Range (2–31) (3–52) (2–46)
Gender (N [%
Male 0 2 (8) 8 (32)
Male castrated 9 (39) 10 (40) 10 (40)
Female 3 (13) 0 1 (4)
Female spayed 11 (48) 13 (52) 6 (24)
ASA status (N
I 18 (78) 16 (64) 19 (76)
II 5 (22) 9 (36) 6 (24)
1Mean, standard deviation (SD) and range for age and weight; significant difference
2 N refers to the number of animals in each category of gender and ASA status; sigversus females. No statistically significant differences in
baseline T, HR, BP or RR were identified across groups
except for a difference in baseline RR between animals
in group 5 (acepromazine/buprenorphine) and group 6
(medetomidine/buprenorphine) (Table 3).
Procedures that dogs underwent during this study
included castration (35), dental prophylaxis and/or tooth
extraction (33), mass removal (19), radiographs (13), surgi-
cal ovariohysterectomy (laparotomy) (10), arthrocentesis,
ear flush, grooming/nail trim (3), gastroscopy, auricular
hematoma repair, cutaneous biopsy, joint injections, mass/
skin tag removal (2) and adipose collection, arthroscopy/
TPLO plate removal, endoscopy, enterotomy, entropion
repair, epidural stem cell injection, gastrotomy, laparoscopic
ovariohysterectomy, and allergy testing, shock wave
therapy, skin testing and splint removal (1). The duration
of procedures (average times per group listed in Table 1)
ranged from less than one minute to 203 minutes.
The range of premedication doses administered to
individual animals across all groups and study sites were:
acepromazine (0.01-0.63 mg/kg [0.005-0.29 mg/lb] SC,
IV or IM); atropine sulfate (0.02-0.075 mg/kg [0.009-
0.03 mg/lb] SC or IM); buprenorphine (0.01-0.033 mg/kg
[0.0045-0.015 mg/lb] SC or IM); medetomidine (0.004-
0.028 mg/kg [0.002-0.013 mg/lb] IV or IM) and midazolam
hydrochloride (0.02-0.48 mg/kg [ 0.009-0.22 mg/lb] SC, IV
or IM). Based on pair-wise mean comparisons following
ANOVA, the dose of acepromazine received in dogs in the
MDP maintenance group was found to be significantly4 5 6 Total
22 22 21 138
ars)1
3.95 2.87 5.67 5.00
3.88 2.67 5.24 4.17
(0.3-12.5) (0.3-10.0) (0.3-17.0) (0.3-17.0)
(kg)1
14.0 20.7 14.8 17.1
9.6 10.5 9.9 11.8
(3–32) (5–41) (2–33) (2–52)
Total])2
8 (36) 13 (59) 7 (33) 38 (28)
2 (9) 2 (9) 7 (33) 40 (29)
4 (18) 5 (23) 2 (10) 15 (11)
8 (36) 2 (9) 5 (24) 45 (33)
[% Total])2
16 (73) 19 (86) 13 (62) 101 (73)
6 (27) 3 (14) 8 (38) 37 (27)
s among groups in mean age with group 2 > groups 4 and 5 (p < 0.05).
nificant differences among groups in gender (p < 0.01).















1 NA (0) 117.2 ± 32.6 (22) 118.0 ± 27.1 (21) 123.7 ± 26.2 (20) 119.7 ± 28.7 (18) 112.9 ± 21.4 (10) 114.8 ± 18.5 (5)
2 113.0 ± 31.0 (25) 112.8 ± 32.2 (25) 116.3 ± 36.2 (23) 110.0 ± 28.7 (21) 112.1 ± 25.4 (19) 101.8 ± 26.7 (17) 94.2 ± 18.5 (14)
3 107.6 ± 28.9 (25) 96.9 ± 25.8 (25) 99.5 ± 34.1 (25) 101.0 ± 30.7 (23) 100.3 ± 26.3 (24) 103.4 ± 22.3 (16) 99.4 ± 19.1 (7)
4 127.8 ± 31.3 (22) 135.9 ± 35.0 (22) 146.8 ± 28.2 (20) 146.8 ± 30.9 (19) 141.7 ± 27.4 (18) 126.7 ± 26.0 (18) 123.1 ± 20.1 (19)
5 116.8 ± 18.9 (22) 145.1 ± 44.0 (22) 142.9 ± 37.3 (21) 158.1 ± 32.0 (20) 134.2 ± 25.2 (21) 124.2 ± 23.6 (21) 114.5 ± 23.4 (20)
6 115.6 ± 33.5 (21) 88.4 ± 36.9 (21) 94.9 ± 27.4 (20) 104.1 ± 26.3 (19) 102.6 ± 22.3 (19) 103.1 ± 20.4 (19) 95.1 ± 18.8 (18)
Statistical
results2
None 4 > (3, 6);
5 > (2, 3, 6)
4 > (2, 3, 6);
5 > (3, 6)
4 > (2, 3, 6);
5 > (1–3, 6)
4 > (2, 3, 6);
5 > (3, 6)
4 > (2, 3, 6);
5 > (3, 6)
4 > (2, 3, 6);
5 > (3, 6)
Respiratory rate
(breaths per min)
1 NA 41.6 ± 13.8 28.6 ± 24.0 31.2 ± 16.7 32.3 ± 26.6 22.6 ± 11.5 23.5 ± 9.8
2 41.1 ± 13.7 36.4 ± 14.9 26.1 ± 15.5 27.1 ± 18.7 30.7 ± 19.9 32.1 ± 18.4 27.0 ± 15.2
3 30.6 ± 13.7 30.3 ± 13.3 23.0 ± 15.2 24.6 ± 11.6 29.3 ± 11.6 27.8 ± 10.8 26.4 ± 15.3
4 34.8 ± 12.0 34.4 ± 11.8 23.9 ± 18.8 25.7 ± 13.3 24.9 ± 19.9 23.3 ± 21.7 26.5 ± 16.9
5 28.6 ± 6.2 29.9 ± 17.5 12.6 ± 9.8 17.4 ± 15.3 17.0 ± 11.6 14.0 ± 6.3 12.6 ± 8.6
6 42.4 ± 17.5 30.7 ± 23.6 12.2 ± 4.5 13.8 ± 6.4 13.8 ± 7.1 14.7 ± 6.7 12.9 ± 5.9
Statistical
results2
6 > 5 None 1 > (5, 6) (1, 2) > 6 (1, 2, 3) > 6 (2, 3) > 5; 2 > 6 (2, 3, 4) > 5;
(2, 4) > 6
Systolic blood
pressure (mmHg)
1 NA 148.0 ± 28.8 128.1 ± 19.9 128.2 ± 32.8 127.2 ± 21.5 115.7 ± 18.2 112.8 ± 14.8
2 141.8 ± 21.3 135.0 ± 30.6 119.6 ± 24.7 113.2 ± 24.0 115.3 ± 28.0 111.1 ± 20.8 115.9 ± 24.4
3 136.6 ± 23.4 126.2 ± 33.6 112.3 ± 21.0 108.8 ± 18.5 112.2 ± 18.7 106.9 ± 17.3 106.1 ± 15.5
4 129.6 ± 23.1 137.4 ± 24.9 122.7 ± 21.3 108.8 ± 15.3 106.4 ± 17.3 105.6 ± 26.7 108.6 ± 31.8
5 137.2 ± 22.3 134.5 ± 16.5 124.4 ± 15.2 112.1 ± 17.1 100.9 ± 11.1 99.8 ± 14.7 101.3 ± 13.7
6 137.1 ± 26.6 128.9 ± 34.5 125.9 ± 40.1 116.2 ± 39.4 127.9 ± 52.1 124.5 ± 36.2 116.6 ± 26.3
Statistical
results2
None None None None (1, 6) > 5 6 > 5 None
Diastolic blood
pressure (mmHg)
1 NA 91.5 ± 33.6 81.1 ± 21.1 79.7 ± 32.2 82.8 ± 22.6 69.4 ± 14.9 74.0 ± 23.8
2 89.0 ± 18.4 86.8 ± 22.8 77.1 ± 27.5 71.2 ± 16.2 73.3 ± 19.0 71.8 ± 22.9 75.1 ± 21.8
3 92.4 ± 26.1 76.9 ± 27.4 70.4 ± 24.0 63.5 ± 18.5 63.8 ± 15.4 57.7 ± 21.3 58.7 ± 15.5
4 87.1 ± 25.8 90.6 ± 28.6 76.2 ± 17.2 62.9 ± 11.6 57.9 ± 15.4 57.6 ± 19.8 60.6 ± 21.6
5 98.8 ± 18.3 89.0 ± 17.8 74.3 ± 19.0 61.3 ± 16.6 55.1 ± 4.6 53.9 ± 9.1 53.2 ± 8.6
6 98.4 ± 25.0 91.4 ± 31.3 90.0 ± 33.6 76.8 ± 35.2 88.2 ± 44.4 79.2 ± 29.2 71.8 ± 20.5
Statistical
results2
None None None None 1 > 5; 6 > (3, 4, 5) 6 > (3, 4, 5) (2, 6) > 5
Mean blood
pressure (mmHg)
1 NA 114.7 ± 27.1 100.2 ± 17.7 101.9 ± 31.7 99.9 ± 20.8 88.1 ± 14.8 90.0 ± 21.4
2 108.9 ± 17.3 102.3 ± 21.0 95.3 ± 24.2 85.8 ± 16.4 90.4 ± 26.0 87.5 ± 21.2 90.4 ± 24.1
3 107.8 ± 24.8 96.2 ± 27.9 86.3 ± 21.3 83.7 ± 16.4 85.5 ± 13.9 78.4 ± 20.7 81.1 ± 16.3
4 103.7 ± 23.8 109.8 ± 25.2 94.4 ± 18.7 78.0 ± 13.6 77.8 ± 15.4 76.6 ± 19.1 77.8 ± 22.0
5 113.1 ± 20.1 105.6 ± 14.3 92.0 ± 18.0 79.7 ± 17.4 72.4 ± 8.9 69.5 ± 9.5 70.3 ± 10.4
6 115.1 ± 24.8 107.1 ± 31.5 105.1 ± 36.2 92.6 ± 33.4 105.6 ± 44.9 99.5 ± 30.5 90.9 ± 19.3
Statistical
results2
None None None 1 > (4, 5) 1 > 5; 6 > (4,5) 6 > (3, 4, 5) (2, 6) > 5
Hb Ox Sat (%)
1 NA NA 90.0 ± 9.9 94.3 ± 3.0 94.5 ± 2.7 95.9 ± 2.2 97.3 ± 1.7
2 NA NA 90.1 ± 6.7 91.8 ± 6.7 93.4 ± 3.5 94.8 ± 2.7 97.7 ± 2.4
3 NA NA 93.9 ± 4.3 94.0 ± 3.9 94.6 ± 2.7 94.8 ± 3.2 97.5 ± 2.4
4 NA NA 95.7 ± 2.4 95.8 ± 2.1 96.7 ± 2.0 96.8 ± 1.7 95.4 ± 1.8
5 NA NA 96.5 ± 1.9 97.6 ± 1.2 97.2 ± 1.5 97.2 ± 1.8 97.0 ± 1.7
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Table 3 Mean ± SD of physiological variable measurements by treatment group (Continued)
6 NA NA 95.6 ± 3.6 96.0 ± 2.4 95.7 ± 2.6 96.5 ± 2.6 96.5 ± 2.6
Statistical
results2
- - (4, 5, 6) > (1, 2) (4, 5, 6) > (1, 2) (4, 5, 6) > 2;
5 > 3
5 > (2, 3) None
End-tidal
CO2 (%)
1 NA NA 28.9 ± 7.9 31.7 ± 8.3 32.5 ± 7.9 36.3 ± 5.5 40.3 ± 9.2
2 NA NA 34.8 ± 12.7 34.1 ± 8.0 38.2 ± 9.2 38.0 ± 9.4 40.4 ± 12.2
3 NA NA 31.6 ± 9.9 35.9 ± 9.8 36.0 ± 7.2 37.7 ± 9.6 47.0 ± 9.6
4 NA NA 34.6 ± 12.2 37.2 ± 9.4 36.8 ± 9.9 36.6 ± 8.7 38.7 ± 5.7
5 NA NA 30.5 ± 7.9 33.7 ± 6.3 36.5 ± 5.9 37.4 ± 4.6 38.4 ± 4.4
6 NA NA 37.0 ± 9.2 41.4 ± 7.3 40.8 ± 9.3 42.0 ± 8.0 43.8 ± 8.2
Statistical
results1
- - None 6 > 1 6 > 1 None None
Rectal temp.
(deg. F)
1 NA 101.7 ± 0.7 101.2 ± 0.8 100.9 ± 0.9 100.4 ± 0.9 100.1 ± 1.2 99.8 ± 1.0
2 101.4 ± 0.7 101.3 ± 0.7 100.8 ± 0.8 100.4 ± 0.7 100.1 ± 0.7 99.8 ± 0.8 99.5 ± 0.8
3 101.3 ± 0.8 100.9 ± 0.7 100.3 ± 0.8 100.0 ± 1.0 99.8 ± 1.3 99.5 ± 1.3 99.1 ± 1.6
4 101.5 ± 0.8 101.2 ± 0.7 100.3 ± 1.3 100.3 ± 0.8 100.2 ± 0.8 99.6 ± 0.9 99.0 ± 1.0
5 101.7 ± 1.0 101.3 ± 0.8 100.6 ± 0.9 100.4 ± 0.9 100.3 ± 0.7 99.9 ± 0.9 99.2 ± 1.1
6 101.9 ± 0.6 101.5 ± 0.9 100.7 ± 1.3 100.5 ± 1.2 100.5 ± 1.3 100.1 ± 1.6 100.0 ± 1.5
Statistical
results1
None 1 > 3 1 > 3 1 > 3 None None None
1Number of animals for physiological variables measured at a given time point.
2Includes all statistically significant (p < 0.05) differences between means for treatment groups at a given measurement time point.
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The mean doses of midazolam and buprenorphine did
not differ significantly between groups assigned to receive
these drugs.
Propofol administration for anesthesia induction began
an average of 27.6 minutes after premedication. The
mean dose of MDP grouped by sedative or tranquilizer
used is shown in Table 4. Dogs receiving no premedica-
tion received a significantly higher mean propofol dose
(7.6 ± 2.1 mg/kg [3.4 ± 1.0 mg/lb]) than all other groups.
Dogs receiving medetomidine for premedication re-
ceived the lowest mean propofol dose (3.2 ± 1.4 mg/kg
[1.4 ±0.6 mg/lb]) for anesthesia induction which was also
significantly less than that for dogs receiving midazolam
(4.7 ± 1.3 mg/kg [2.1 ± 0.6 mg/lb]), but not acepromazine
(4.0 ±1.0 mg/kg [1.8 ± 0.5 mg/lb]). Actual administration
time until the anesthetic endpoint for intubation ranged
from 30 to 145 seconds resulting in rates of injection
between 0.9 to 8.0 mg/kg/min (0.4 to 3.6 mg/lb/min).Table 4 Mean total multi-dose propofol (MDP) required for in
Premedicant None Midaz
Number of animals 23 4
Total MDP dose (mg/kg)2 7.55 4.
Standard deviation 2.14 1.
Range 4.6-16.0 2.2
1Sedative and tranquilizers given in combination with buprenorphine; use of antich
2Statistically significant (p < 0.05) differences: None > (Midazolam, Acepromazine anInvestigators rated the quality of induction as excellent
in 82 (59%), good in 47 (34%), fair in 8 (6%) and poor in 1
(<1%) of the 138 animals included in this study. Four of
the nine inductions judged fair or poor involved dogs that
were premedicated with midazolam/buprenorphine and in
whom additional propofol was required for anesthesia
induction. In groups maintained with propofol, the mean
duration of anesthesia after the initial or induction dose
(until subsequent dosing) was 5.8, 5.5 and 6.5 minutes
in groups 1, 2 and 3, respectively.
The duration of anesthesia after the administration of
each individual maintenance dose of MDP ranged from
1.7 to 20 minutes in unpremedicated animals (group 1)
and 1 to 12.5 minutes in both groups of premedicated
animals (groups 2 and 3). The total maintenance time
(intubation to last administered dose) for groups 1–3
ranged from 1.7 to 37 minutes. The average additional
propofol administered for maintenance of anesthesia in






olinergics was optional. See text for additional detail.
d Medetomidine) and Midazolam >Medetomidine.
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and 2.0 ± 1.2 mg/kg (0.9 ± 0.5 mg/lb), respectively. This av-
eraged to a mean maintenance dose rate of 0.48 mg/kg/min
(0.22 mg/lb/min) in group 1 (non-premedicated animals)
and 0.31 mg/kg/min (0.14 mg/lb/min) and 0.4 mg/kg/min
(0.18 mg/lb/min) in group 2 (midazolam/buprenorphine)
and group 3 (acepromazine/buprenorphine), respectively.
These results were not significantly different. The total
maintenance doses in groups 1, 2 and 3 ranged from 0
(no additional maintenance doses administered) to
24.7 mg/kg MDP. The average total doses (ranges) of
MDP (induction plus maintenance), administered to
groups 1, 2 and 3 were 10.1 (5.1-30.0), 9.3 (3.9-23.8) and
8.0 (2.5-28.7) mg/kg, respectively.
Of the two inhaled anesthetics used during the course
of the study, isoflurane use accounted for 85.5% of the
cases maintained by inhalant. Total maintenance time
with inhalant anesthetics (groups 4–6) ranged from 16.2
to 245 minutes. Initial mean vaporizer settings were 2.1%
for isoflurane and 3.7% for sevoflurane. Mid-maintenance
vaporizer settings were 1.8% for isoflurane and 3.5% for
sevoflurane. Nine animals received supplemental propo-
fol during inhaled anesthetic maintenance to enhance
the quality of anesthesia. Apnea occurred in one animal
in conjunction with the administration of a supplemental
dose of MDP.
Quality of maintenance with propofol alone was rated
as good or excellent in 86% of patients overall; 100% of
patients in group 1 and 68 and 92% of patients in groups
2 and 3, respectively. In group 2, quality of maintenance in
24% of the animals was rated as fair and 8% rated as poor.
Quality of maintenance was rated fair in a single group 3
animal (4%) and was unrecorded in another one (4%).
Mean (±SD) recovery times are presented in Table 5.
No statistically significant differences were noted in time to
extubation, and only sporadic differences between treat-
ment groups were noted for times to sternal recumbency
(group 2 vs. group 4) and to standing (groups 2 and 5 vs.
group 1). Investigators evaluated the quality of recovery as
good to excellent in 91, 76 and 92% of animals in groups 1,
2 and 3, respectively, with the remaining animals receiving a
rating of fair. In dogs recovering from inhalation anesthesia,
the quality of recovery was rated as good to excellent in 82,
81 and 81% of the animals in groups 4, 5 and 6, respectively.
Eleven percent of animals in these groups received a rating
of fair, and 5% (three animals) were rated as poor.
Mean values for physiological parameters prior to
premedication and anesthesia induction and during the
first 30 minutes of anesthesia are presented in Table 3.
Differences between groups observed at each time point
for measured parameters are also indicated in the table.
Average HR was highest in groups 4 and 5. Significant dif-
ferences were observed between groups 4 and 5 and groups
2, 3 and/or 6 at various time-points after premedicationand between groups 5 and 1 at 5 minutes post-induction.
Average RR tended to be higher in groups 1–4 compared
to groups 5 and 6. Significant differences were observed
between groups 1 and 6 immediately and up to 10 minutes
post-induction, between groups 1 and 5 immediately post-
induction and between groups 2, 3 and 4 compared to
groups 5 and/or 6 at various time-points during inhalant
maintenance. Average BP (S, D or M) tended to be highest
in groups 1, 2 and 6 with significant differences between
groups 3, 4 and/or 5 observed during the maintenance
period. Although not statistically significant overall, a
decrease in SBP was observed in 56% of the animals
immediately post-induction.
Average SpO2 tended to be highest in groups maintained
on inhalant, with results in groups 4, 5 and 6 significantly
greater than those in groups 1 and 2 immediately and at
5 minutes post-induction and greater than those in group 2
at 10 minutes post-induction. The SpO2 was also signifi-
cantly greater in group 5 than in groups 2 and 3 at vari-
ous time-points during maintenance anesthesia. There
were 25 animals in which SpO2 <90% was reported, gen-
erally immediately post-induction. Most of these animals
(23/25) were maintained on MDP (groups 1–3). Of the
group 1–3 animals, apparent hemoglobin desaturation was
exclusively observed in animals not receiving supplemental
oxygen. In four of these animals, supplemental oxygen was
provided, but in the remaining 19 dogs, the transient appar-
ent hemoglobin desaturation resolved without treatment.
The ETCO2 tended to be highest in group 6 and was sig-
nificantly greater than group 1 immediately and at 5 mi-
nutes post-induction. Rectal temperature was significantly
greater in group 1 compared to group 3 prior to induction
and immediately and at 5 minutes post-induction.
Table 6 summarizes clinical side effects and adverse
events by group. The most frequently observed side ef-
fect was hypotension which generally occurred during
inhalation anesthesia. In 12 of the 16 affected animals,
additional intravenous fluids and/or ephedrine was
used to treat low blood pressure. Apnea, the second
most common clinical side effect observed, typically
occurred within the first five minutes after induction.
Apnea lasting 120 seconds occurred more commonly
in group 2, usually when animals received a midazolam
dose of 0.3 mg/kg or greater. As a result of prolonged
apnea, five animals in this group received supplemental
oxygen. Bradycardia occurred mainly during anesthesia
maintenance and was seen most frequently in animals
premedicated with medetomidine (n = 6), two of which
had also received atropine premedication. Atropine or
glycopyrrolate was used in four instances to treat low
heart rate. Tachycardia was observed in two animals,
both in the presence of atropine. In one of the dogs, a heart
rate of 177 was observed immediately after premedication
with acepromazine and atropine. No increase in heart rate
Table 5 Geometric mean recovery times for dogs by treatment group1
Group Time to extubation2 (min) Time to sternal recumbency2 (min) Time to standing2 (min)
Geometric mean (GSD)/range
1 8.0 (1.82) 2 – 41 9.7 (1.67) 3 – 44 14.6 (1.54) 8 – 56
2 11.1 (1.76) 5 – 41 15.2 (1.71) 6 – 45 24.4 (1.58) 10 – 48
3 10.1 (1.71) 4 – 25 13.3 (1.69) 5 – 29 18.7 (1.68) 7 – 48
4 7.3 (1.86) 3-36 8.8 (1.74) 4-38 15.2 (1.97) 4-55
5 9.0 (1.94) 3-33 12.4 (1.87) 3-41 24.0 (1.98) 5-115
6 8.0 (1.72) 4-22 10.6 (1.68) 4-25 18.1 (1.90) 6-105
Statistical results2 None 2 > 4 2, 5 > 1
1Time measured from last propofol injection (Groups 1–3) or vaporizer off (Groups 4–6). See text for additional details.
2Includes all statistically significant (p < 0.05) mean differences between treatment groups based on log-transformed data.
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heart rate increased to 253 bpm at the 0–5 minute
interval, returning to 128 bpm at 5–10 minutes. In the sec-
ond animal, (group 4) no increase in heart rate was ob-
served immediately after injection of MDP, but increases up
to 167 bpm were observed throughout the 30 minutes of
inhaled anesthetic maintenance. Hypertension was re-
corded in three group 6 animals in which MAP ranged from
142–215 mmHg; all three animals had received atropine.
Pain on injection of MDP was not observed in this study.
There was one death associated with an animal included
in the study. This occurred 2 days post ovariohysterectomyTable 6 Number of animals per group with side effects* or ad
1 2
Number of patients in group 23 25
Number of patients receiving atropine 0 0
Side effect (Adverse event) No. pa
Hypotension 1 (1)
Apnea 1 (2) 6 (6)













*Quantitative side effects defined as physiological measurements outside the norm
**Quantitative adverse reactions defined as: heart rate less than 50 bpm, apnea >12
ECG rhythm, mean O2 saturation <80% (any duration) or 90% for > 3 min.in a 6-year-old female Jack Russell Terrier assigned to
group 5. A post-mortem examination was performed,
and the cause of death was attributed to septic peritonitis
from an ovarian pedicle abscess consistent with introduc-
tion of a foreign material at the time of surgery. Three
other dogs were treated from the same vial of MDP with-
out incident; one was treated before and two after the dog
experiencing the adverse event.
The maximum duration of use for any individual vial
used during the course of the study was 17 days, and the
maximum number of withdrawals (needle penetrations)
was nine. Approximately 50% of the vials were used oververse events** recorded during the study
Treatment group Total
3 4 5 6
25 22 22 21 138
1 10 21 6 38
tients experiencing side effect or adverse event ( )
1 (1) 3 (2) 9 (1) 2 (2) 16 (7)
2 (1) 3 (2) 3 (1) 15 (12)
2 (1) 1 1 6 (6) 11 (9)
1 6 2 1 13
3 1 7





1 (1) 2 (1)
1 1 2
1 2
1 (1) 1 (1)
(1) 1 (1)
al range.
0 seconds, mean arterial blood pressure < 50 mmHg, any potentially lethal
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for two days during which three withdrawals were made.
Investigators did not observe a change in dosing or re-
duction in quality of maintenance for those animals who
were dosed at the end of the use interval for any vial.
Discussion
Prior multicenter clinical studies have confirmed propofol
as a fast-acting anesthetic agent, with a favorable recovery
and safety profile [1,3]. The single-use formulations of this
drug, however, do not allow multiple withdrawals for
more than six hours from first penetration which can re-
sult in wastage of the unused drug. The purpose of this
study was to demonstrate the safety and efficacy of MDP
under a wide range of clinical circumstances. Results of
this study suggest that the addition of benzyl alcohol to
the formulation of the sterile injectable has the potential
to reduce wastage by allowing a shelf-life of up to 28 days
after the initial withdrawal/needle penetration without
altering the safety or efficacy of the preparation. While
direct comparisons cannot be made in the absence of
control groups in which preservative-free propofol was
used, results of dosing and prevalence of side effects
can be compared to those from published studies on
single-use propofol.
The population in this study consisted of healthy indi-
viduals with an average age of 5 years; the youngest dog
was 3 months old. The use of benzyl alcohol as a preser-
vative in human parenteral solutions has been associated
with a rare but fatal neonatal gasping syndrome in pre-
mature human infants and some immature animals
[7,8]. Exposure associated with toxicities was at or
above 99 mg/kg/day, a level well above exposure en-
countered with the use of MDP for induction and short
term maintenance of anesthesia in this study. However
given the exclusion of dogs less than 10 weeks of age, we
cannot make any recommendations regarding use for this
population of patients. Similarly, due to the use of MDP
for only a short duration in this study (up to 37 minutes)
we cannot comment on the safety of MDP for prolonged
infusion as has been previously described for preservative-
free propofol [9].
The induction doses in this study for unpremedicated
animals were slightly higher than reported for single-use
propofol [1,3]. The reasons for this difference are likely
multifactorial. For example, population differences and
factors related to the study, such as stimulating animals
to record physiological parameters prior to induction,
may have played a role. In addition, the rate of propofol
administration may have influenced the total dose. For
this study, the recommended rate of administration was
60 and 90 seconds or until the patient could be intubated.
This was suggested in an effort to minimize any cardiopul-
monary depression as is common after a rapid intravenousbolus of a fixed dose. Interestingly, prior reports suggest
that slow administration can decrease [10,11] or increase
[12,13] the amount of propofol used to achieve a fixed
endpoint. It is thought that, while a slower rate allows
for more gradual equilibration of the blood and brain
concentrations, anesthesia may not be achieved if this
is excessively prolonged [10,13]. Induction doses of 6.5
and 5.5 mg/kg are reported with administration of
single-use propofol over 60–90 versus 10–30 seconds
[1,3]; the results in this study are similar to the study
in which the slower injection rate was used.
Unlike results in unpremedicated animals, the range of
mean doses to achieve induction in premedicated animals
were similar to that previously reported for single-use
propofol [1-3,12-17]. In the current study, the presence of
premedication reduced the propofol induction dose by 38,
47 and 58% for midazolam/buprenorphine, acepromazine/
buprenorphine and medetomidine/buprenorphine com-
binations, respectively. A greater dose-sparing potency
of medetomidine compared to that of midazolam or acepro-
mazine has been reported for single-use propofol [18-21].
The mean duration of anesthesia for MDP (recorded
from end administration to requirement for first additional
dose) was comparable to that previously reported for
single-use propofol for both unpremedicated and pre-
medicated animals [1-3,13]. Similar to results reported
for the single-use propofol [12,15], the dose required to
maintain anesthesia remained consistent over time, sug-
gesting that the MDP did not accumulate upon repeated
administration over a short period of time.
Differences in premedicant doses, the use of atropine and
supplemental oxygen, surgical procedures, and monitoring
methods among the study animals and sites likely contrib-
uted to variations in physiologic measurements, and may
have influenced the ability to detect differences among the
treatment groups. Overall, however, the effects of MDP
on physiological variables mirrored those seen in prior
reports including multicenter clinical trials with single-use
preparations [1,3,18,22-25]. The most common findings in
all of these studies include a decrease in blood pressure
and respiratory rate after propofol administration with
minimal to no effects on heart rate beyond that observed
with premedication. This suggests that the addition of ben-
zyl alcohol to the formulation did not have any significant
additional cardiovascular or respiratory effects. Tachycardia
was reported in only two dogs in this study, both premedi-
cated with atropine, which is likely to have played a role.
The low incidence of tachycardia in this study differs from
results observed in a tolerance study of MDP in which
increases in heart rate were observed immediately after
induction with MDP. The phenomenon appeared to be
dose-related, with a maximum heart rate of 230 beats
per minute seen at a dose of 19.5 mg/kg with little effect
observed at 6.5 mg/kg [5]. It is unlikely that a dog would
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under typical clinical conditions. Consistent with other
reports, heart rate was lowest in medetomidine-treated
groups [24].
In all but the medetomidine premedicated dogs (group 6),
average S, D and M blood pressure tended to decrease
following MDP induction. This has been attributed
previously to propofol induced veno-dilation which
decreases cardiac preload [25]. The vasoconstriction
induced by medetomidine likely offset these effects
[26,27]. Respiratory rate decreased numerically in all
groups following induction of anesthesia but the mean
decrease was not statistically significant for any group.
Interestingly, ETCO2 tensions tended to remain within the
normal range throughout the study. Blood gas measure-
ments would have helped determine the degree to which
the decrease in RR may have contributed to changes in
ventilation in individual animals but were not performed in
this study. The average SpO2 immediately post-induction
was 90.0 ± 9.9, 90.1 ± 6.7 and 93.9 ± 4.3 in groups 1, 2 and
3, respectively, the MDP maintenance groups (Table 3).
This apparent hemoglobin desaturation was likely due
to a combination of respiratory depression and drug or
recumbency-induced ventilation perfusion abnormal-
ities. Arterial blood gas analysis may have helped fur-
ther elucidate the cause. Prior reports on a single-use
preparation suggest that propofol-induced respiratory
depression is exacerbated when sedating drugs and Mu
(OP3) agonist opioids are used with propofol [21,28].
Approximately 37% of animals in the MDP mainten-
ance groups (1–3) received supplemental oxygen prior
to induction. Of those not receiving supplemental oxy-
gen, the average SpO2 immediately post-induction was
85.3 ± 11.4, 86.2 ± 6.3 and 91.0 ± 5.2 in groups 1, 2 and 3,
respectively. Although the low SpO2 was transient in dogs
maintained on MDP, these data support the recommenda-
tion to provide supplemental oxygen to animals maintained
on propofol [2]. The higher SpO2 observed in dogs main-
tained on inhalant anesthetics was expected, as these dogs
were breathing a high fraction of inspired oxygen. This was
similar to dogs in the MDP maintenance groups which
received supplemental oxygen (average SpO2 immedi-
ately post-induction 95.1 ± 1.4, 94.8 ± 2.8 and 95.8 ± 1.9
in groups 1, 2 and 3, respectively).
The side effects observed were qualitatively comparable
to those seen with the single-use product [1,3,5,13-17,19]
and were predominantly related to the cardiovascular and
respiratory systems. Apnea was more commonly seen dur-
ing maintenance with propofol than inhaled anesthesia,
but the incidence was lower than or comparable to that
reported previously for the single-use product. The distri-
bution of other cardiovascular effects between those ani-
mals administered propofol versus inhaled agents tended
to mirror observations with single-use propofol, with theexception of hypotension, which was observed less fre-
quently than expected in the MDP maintenance groups in
this study. Other observed side effects were in keeping with
those associated with specific premedicants. For example,
poor sedation [29,30] and excitement has been reported as a
side effect of midazolam [31], and hypertension has been as-
sociated with medetomidine [26,27] and the combination of
medetomidine and atropine [29]. Abnormal ECG rhythms
were observed only during inhaled anesthetic maintenance
specifically in groups 4 and 5 (with 1 animal in each group).
However, it was more common for dogs in these groups
to be monitored in this manner. No ECG abnormalities
were observed in a tolerance study of MDP at doses up to
19.5 mg/kg [5].
The toxicity of benzyl alcohol has been characterized
in the dog [32] as well as other species [33-35]. Cardio-
vascular, respiratory and central nervous system effects,
such as tremors, have been documented. Significant species
differences have been noted, with the cat being particularly
sensitive to benzyl alcohol toxicity, which is attributed to
its glucuronide deficiency [36]. Parenteral toxicity of ben-
zyl alcohol is also reported to be dependent on concentra-
tion in solution and rate of administration [32]. In the
current study, the physiologic and clinical side effects of
MDP were similar to those documented for single-use
propofol. Also, side effects were not seen at higher levels
in the groups maintained on MDP, despite their higher ex-
posure. Thus, no specific adverse findings could be attrib-
uted to the addition of benzyl alcohol to the formulation.
Despite the reported sensitivity of cats to benzyl alcohol,
the anesthetic, physiologic and side effect profiles of MDP
were also found to be similar in cats to those of single-use
propofol [37].
There was no evidence of infection or sepsis as a result
of MDP administration; the single case in which septic
peritonitis was observed was attributed by the pathologist
to the introduction of foreign material at the time of
surgery. The use of the same vial of MDP in two dogs
after the dog experiencing the adverse event precluded
additional testing on this vial for contamination. How-
ever, laboratory testing of the MDP with repetitive nee-
dle punctures over the 28 days support the sterility of
the product over the shelf-life [38].
The fact that approximately 50% of the vials were used
over the course of at least two days, indicates that a pre-
servative containing formulation can help eliminate waste
from product remaining after the 6-hour recommended
period for single-use (preservative-free) propofol.
Conclusions
Based on the results of this study, MDP was found to be
acceptable for use in ASA I and II dogs for induction and
short term maintenance of anesthesia or induction of
anesthesia prior to maintenance with inhaled anesthetics
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premedicants. Induction and maintenance dose, duration
of anesthesia after a single-use and anesthesia quality were
comparable to those reported previously for single dose
propofol. At clinically effective doses, no adverse effects
could be directly linked to the addition of 2% benzyl alco-
hol used as a preservative in this formulation. The inclu-
sion of benzyl alcohol in the formulation allowed the use
of one propofol vial for up to 9 needle insertions for drug
withdrawal over a period up to 17 days.
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